CU20090062A7 - USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID - Google Patents
USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBIDInfo
- Publication number
- CU20090062A7 CU20090062A7 CU20090062A CU20090062A CU20090062A7 CU 20090062 A7 CU20090062 A7 CU 20090062A7 CU 20090062 A CU20090062 A CU 20090062A CU 20090062 A CU20090062 A CU 20090062A CU 20090062 A7 CU20090062 A7 CU 20090062A7
- Authority
- CU
- Cuba
- Prior art keywords
- estradiol
- combination
- dienogest
- 17beta
- maintain
- Prior art date
Links
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title abstract 5
- 229960005309 estradiol Drugs 0.000 title abstract 3
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 title abstract 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 title abstract 2
- 229960003309 dienogest Drugs 0.000 title abstract 2
- 229960004766 estradiol valerate Drugs 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 108010091205 Libid Proteins 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se relaciona con el uso de valerato de estradiol o 17beta-estradiol (estradiol) en combinación con 17a-cianometil-17-beta-hidroxiestra-4,9-dien-3-ona (dienogest) en un producto combinado de múltiples fases o de una solafase en una terapia oral para mantener y/o incrementar la líbido femenina, cuando fuera apropiado también junto con una contracepción oral. Las unidades de dosis diarias totales de la combinación de múltiples fases y del placebo farmacéuticamente aceptable o las unidades de dosis diarias de la combinación de una sola fase y sin ingrediente activo y sin place4bo corresponden a 28 días.The invention relates to the use of estradiol valerate or 17beta-estradiol (estradiol) in combination with 17a-cyanomethyl-17-beta-hydroxystra-4,9-dien-3-one (dienogest) in a combined multi-phase product or from a single phase in an oral therapy to maintain and / or increase female libido, when appropriate also along with an oral contraception. The total daily dose units of the multi-phase combination and the pharmaceutically acceptable placebo or the daily dose units of the single phase combination without active ingredient and without place4bo correspond to 28 days.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090062A CU20090062A7 (en) | 2009-04-20 | 2009-04-20 | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090062A CU20090062A7 (en) | 2009-04-20 | 2009-04-20 | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20090062A7 true CU20090062A7 (en) | 2011-04-26 |
Family
ID=44303524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20090062A CU20090062A7 (en) | 2009-04-20 | 2009-04-20 | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID |
Country Status (1)
| Country | Link |
|---|---|
| CU (1) | CU20090062A7 (en) |
-
2009
- 2009-04-20 CU CU20090062A patent/CU20090062A7/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009003231A (en) | USE OF ESTRADIOL VALERATE OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR IMPLEMENT FEMALE FREE | |
| AR124134A2 (en) | TOPICAL USE FORMULATION FOR A JAK INHIBITOR | |
| ECSP10010224A (en) | LUTEINIZING HORMONE LIQUID FORMULATIONS (LH). | |
| NO20081038L (en) | Pharmaceutical formulations / compositions of guanfacine suitable for daily single dosage form administration | |
| CO6630107A2 (en) | Solid oral dosage forms with very low doses for hrt | |
| MX2016010213A (en) | Novel pharmaceutical formulations. | |
| ES2478264T3 (en) | Glyerosomes and their use in pharmaceutical and cosmetic preparations for topical application | |
| MX2015009772A (en) | Spiro-lactam nmda receptor modulators and uses thereof. | |
| EA201491479A1 (en) | DERIVATIVES OF LUPANOV TRITERPENOIDS AND THEIR PHARMACEUTICAL APPLICATIONS | |
| TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
| AR065816A1 (en) | ORAL CONTRACEPTIVE REGIME | |
| AR086400A1 (en) | FORMULATIONS IN INTRANASAL GEL OF TESTOSTERONE IN DOSE OF LOWER POWER AND USE OF THE SAME FOR THE TREATMENT OF ANORGASMIA OR THE DISORDER OF HYPOACTIVE SEXUAL DESIRE | |
| AR075866A1 (en) | A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION | |
| ECSP099482A (en) | PHARMACEUTICAL PREPARATION TO REDUCE ENDOMETRIOSIS | |
| CU20090062A7 (en) | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID | |
| DOP2009000079A (en) | USE OF ESTRADIOL VALERATE IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID | |
| MX2010013484A (en) | Pharmaceutical formulation of ketorolac for intranasal administration. | |
| MX2009008813A (en) | PHARMACEUTICAL COMPOSITION CONTAINING FLOROGLUCINOL AND PARACETAMOL. | |
| CO2022000211A2 (en) | Pharmaceutical compositions resistant to dose discharge comprising comeunad | |
| AR086252A1 (en) | TOPICAL FORMULATION THAT INCLUDES BECLOMETASONE DIPROPIONATE AS ACTIVE INGREDIENT | |
| BR112015010650A2 (en) | improved levonorgestrel-containing composition only for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation | |
| CL2012003685A1 (en) | Pharmaceutical kit comprising one or more packaging units comprising 21 to 28 daily active dosing units in which each comprises at least 2 mg of drosperidone, without spoiling us; use of the kit and a pharmaceutical composition comprising drosperidone to prepare a useful medication as a contraceptive. | |
| EP4389147A3 (en) | Therapeutic formulations and uses thereof | |
| AR070886A1 (en) | NEW DROSPIRENONA REGIME / 17 BETA-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS SET (KIT) FOR APPLICATION | |
| AR072246A1 (en) | DROSPIRENONA REGIME / 17 BETA -ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS ASSEMBLY (KIT) FOR APPLICATION |